Curated news and analysis on clinical trials, drug approvals, and medical research.
The FDA approved Tregzi (Orca-T), a first-of-its-kind regulatory T cell-based immunotherapy, for adults with blood cancers undergoing matched donor stem cell transplants. Approval was based on the PRECISION-T trial, in which 78% of treated patients achieved chronic GVHD-free survival at one year versus 38.4% with standard transplant.
Biotechnology is now a national security issue in Washington, with investment restrictions, export controls, and procurement bans targeting China. The Pentagon designated WuXi AppTec as a Chinese military company, sparking a legal challenge. Policymakers also warn about supply chain dependence, biosecurity, and the dual-use dilemma.
A drug-free wearable device that generates low-intensity electric fields reduced tumor growth and spread in preclinical models of triple-negative breast cancer. The treatment appeared to boost immune activity around tumors and will be tested in an upcoming NIH-sponsored clinical trial.
AI is transforming drug discovery across target ID, molecule design and trial optimization. Milestones include regulatory qualification of digital-twin controls and positive Phase 2a data, though 90-95% of candidates still fail.
An enzyme-based method built over 120 DNA-barcoded molecules under mild conditions for DNA-encoded libraries. Another study's ErePOC model predicted DEL-suitable protein pockets with 98% precision.
China has become the dominant source of external drug innovation, with pharma licensing deals reaching $135.7 billion in 2025 and China developing 30% of the world's new innovative drugs. Meanwhile, India is expanding AI use in drug discovery and strengthening its CRDMO and IP infrastructure, though investment gaps persist.
Moderna posted a narrower-than-expected Q2 loss, with mFLUSIVA awaiting an FDA decision and a Phase 3 norovirus trial missing early success criteria. It reaffirmed 2026 revenue growth and cash guidance.
Vidac Pharma's CEO will present at the 19th Annual European Life Sciences CEO Forum in Zurich on March 4–5, 2026, covering clinical advancements and pipeline expansion. Lead candidate VDA-1102 has shown efficacy in Phase 2b actinic keratosis and Phase 2A cutaneous T-cell lymphoma.
FDA approved Viridian's Lumvoa (veligrotug-vvze) for thyroid eye disease on June 26, 2026; immediate U.S. launch followed. Q2 2026 cash stood at $982 million, and elegrobart BLA submission is on track for Q1 2027.
Novel AAV and MSC-based delivery systems advance gene therapy in preclinical studies, while the field shifts toward nonviral platforms. Utilization rates grew 42% and per-member-per-year spending doubled from 2022 to 2024.
Lyell Immunopharma initiated the Phase 3 PiNACLE–H2H trial of ronde-cel in large B-cell lymphoma and reported that GI prophylaxis reduced severe diarrhea rates from 55% to 10% in the Phase 1 LYL273 trial.
BioMarin reported Q2 2026 revenues of $990 million, up 20% Y/Y, and raised guidance. It filed an sNDA for VOXZOGO in hypochondroplasia and advanced BMN 333, BMN 820, and BMN 351.
Biotech companies posted Q2 2026 results: REGENXBIO's Duchenne trial met its primary endpoint, Compass Pathways' COMP360 NDA submission is on track for Q4, Puma raised full-year guidance on NERLYNX demand, and Evotec cut its 2026 outlook.
Several biopharmaceutical companies reported Q1 2026 results: Incyte revenue rose 21% to $1.27B, Compass reported positive tovecimig data in biliary tract cancer, and Precision, Intensity and Evofem advanced pipelines.
Pilot genetic testing at ESMO Breast Cancer 2026 found inherited variants in 8.6% of breast and 10.1% of ovarian cancer survivors. A systematic review linked mammographic surveillance to a 50% lower mortality risk.
A global investment firm agreed to acquire a medical device maker for $5.7 billion, while Juvisé Pharmaceuticals secured a $652 million refinancing and Pharmacelera raised $7.1 million. A biotech company also completed a $289 million IPO, and the MHRA issued AI guidance.
Real-world data show trastuzumab deruxtecan achieved a 56.3% response rate and 7.4-month median progression-free survival in HER2-low metastatic breast cancer. Preclinical findings show HER2-low subclones can drive ADC resistance, and experts say T-DXd is now standard for HER2-low disease, with DESTINY-Breast15 studying HER2-null patients.
Astellas Pharma reported fiscal 2026 sales of ¥2.14 trillion and net income of ¥291.54 billion, alongside an FDA Priority Review for PADCEV plus Keytruda in muscle-invasive bladder cancer. The company also settled U.S. Myrbetriq patent disputes with Lupin and Zydus. Shares trade at ¥2,470 with mixed valuation signals.
FDA approved Moderna's mRNA flu vaccine for older adults, the first licensed mRNA flu shot. Measles cases continue to climb, and the CDC issued new advisories. A Nature study linked Covid to dormant virus reactivation.
Insmed reported Q2 2026 revenues of $425.5M, with BRINSUPRI at $309.2M. It raised 2026 BRINSUPRI guidance to $1.25B-$1.40B and lifted peak revenue estimates for its lead programs to over $14B.
